Cancer: Antitumor effects of octreotide LAR, a somatostatin analog

Nature Reviews Endocrinology

Volumn 6, Issue 4, 2010, Pages 188-189

  Oberg, Kjell ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; OCTREOTIDE; PLACEBO; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5;

ANGIOGENESIS; CANCER CONTROL; CARCINOID SYNDROME; CELL PROLIFERATION; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; FLUSHING; HUMAN; METASTASIS; MIDGUT; MIDGUT CARCINOID TUMOR; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY; TUMOR GROWTH; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; DELAYED-ACTION PREPARATIONS; DISEASE PROGRESSION; HUMANS; INTESTINAL NEOPLASMS; NEOPLASMS; NEUROENDOCRINE TUMORS; OCTREOTIDE; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOMATOSTATIN; TUMOR BURDEN;

EID: 77950274160     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2010.3     Document Type: Short Survey

References (10)

1. Yao, J. C. et al. One hundred years after "carcinoid ": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United states. J. Clin. Oncol. 26, 3063-3072 (2008).
2. Feldman, J. M. Carcinoid tumors and syndrome. Semin. Oncol. 14, 237-246 (1987).
3. Oberg, K. et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann. Oncol. 15, 966-973 (2004).
4. Rinke, A. et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMiD study Group. J. Clin. Oncol. 27, 4656-4663 (2009).
5. Plockinger, U. & wiedenmann, B. neuroendocrine tumors. Biotherapy. Best Pract. Res. Clin. Endocrinol. Metab. 21, 145-162 (2007).
6. Reubi, J. C., waser, B., schaer, J. C. & Laissue, J. A. somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur. J. Nucl. Med. 28, 836-846 (2001).
7. susini, C. & Buscail, L. Rationale for the use of somatostatin analogs as antitumor agents. Ann. Oncol. 17, 1733-1742 (2006).
8. imtiaz, K. E., Monteith, P. & Khaleeli, A. Complete histological regression of metastatic carcinoid tumor after treatment with octreotide. Clin. Endocrinol. 53, 755-758 (2000).
9. Granberg, D., Jacobsson, H., Oberg, K., Gustavsson, J. & Lehtihet, M. Regression of a large malignant gastrinoma on treatment with sandostatin LAR: a case report. Digestion 77, 92-95 (2008).
10. Rindi, G. et al. TnM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 451, 757-762 (2007).